Published on 8 May 2024 on Zacks via Yahoo Finance
Ligand Pharmaceuticals Incorporated LGND reported core adjusted diluted net income per share of $1.20 in first-quarter 2024 from continuing operations. Although earnings declined 10% year over, the figure still beat the Zacks Consensus Estimate of $1.13.
Total revenues of $31.0 million were down 30% from the year-ago quarter’s levels. The reported figure missed the Zacks Consensus Estimate of $32.5 million.